FDA approves new combination antihypertensive

Julia Rommelfanger

September 07, 2000

Thu, 07 Sep 2000 14:53:43

Wayne, PA - The FDA has approved a new antihypertensive, Atacand HCT?, a combination of the angiotensin II receptor blocker candesartan cilexetil (Atacand®) and the diuretic hydrochlorothiazide, both of which have been previously approved, the drug's manufacturer, AstraZeneca, announced.

Atacand HCT, available in two combinations, 32 mg candesartan cilexetil - 12.5 mg hydrochlorothiazide, and 16 mg candesartan cilexetil - 12.5 mg hydrochlorothiazide, is indicated for second-line treatment of hypertension as another treatment option for patients unable to control their blood pressure with a single agent, the company said.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.